MEA 呼吸道感染治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00038996
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 201
Buy Now

MEA 呼吸道感染治疗市场规模预计将从 2023 年的 20.928 亿美元增长到 2031 年的 29.7509 亿美元,复合年增长率为 4.50%。

市场洞察和分析师观点:

呼吸道感染(RTI)是鼻窦、喉咙、气道或肺部的感染。虽然大多数 RTI 会自行缓解,但有时可能需要去看医生。 MEA 呼吸道感染治疗市场报告强调了推动市场的关键因素,并描述了知名参与者的发展。推动市场增长的关键因素包括中东呼吸道感染病例的增加以及对呼吸道感染相关意识的提高。然而,缺乏针对呼吸治疗的研究阻碍了市场的增长。此外,MERS 抗病毒治疗的出现预计将在未来几年带来新的 MEA 呼吸道感染治疗市场趋势。

增长驱动因素和限制:

中东一直在经历呼吸道感染病例增加,主要是由于空气污染、吸烟流行、拥挤的生活条件和季节性病毒爆发等因素造成的。根据 NCBI 2019 年发布的数据,急性下呼吸道感染是一个严重的健康问题,每年影响近 15% 的沙特人口。过去三十年进行的流行病学研究表明,大多数这些疾病是由病毒引起的。根据阿联酋沙特德国医院集团的数据,迪拜约 13% 的成年人和约 20% 的儿童患有哮喘,这是一个严重的健康问题。生活方式决定、遗传倾向和环境触发因素等变量可能与哮喘的高发病率有关。呼吸道感染负担的增加产生了对有效治疗方案的需求。制药公司通过开发和提供创新疗法来利用这种不断增长的需求。此外,通过重点关注研发、公私合作伙伴关系和提高认识举措,它们可以在应对中东呼吸道感染带来的挑战方面发挥至关重要的作用。

全面临床试验的可用性有限中东和非洲地区呼吸药物的药理学评估和现实世界证据阻碍了针对该地区独特医疗保健环境的新型治疗方法、优化治疗指南和循证实践的开发。由于缺乏有关呼吸治疗的功效、安全性和成本效益的特定区域研究数据,这给设计有针对性的治疗策略、推断区域疾病模式和优化患者治疗结果带来了挑战。此外,缺乏研究可能会阻碍新出现的呼吸道病原体的识别、评估治疗反应以及探索适合该地区特定医疗保健需求的最佳药物治疗方案。专门针对呼吸治疗的研究的缺乏限制了 MEA 呼吸道感染治疗市场的增长。

战略见解

报告细分和范围:

MEA 呼吸道感染治疗通过考虑以下细分市场进行了市场分析:药物、疾病适应症、给药途径、年龄组和分销渠道。根据药物,市场分为抗生素、非甾体抗炎药、止咳药、鼻减充血剂等。按疾病适应症,MEA呼吸道感染治疗市场分为上呼吸道感染和下呼吸道感染。就给药途径而言,市场分为口服和肠胃外。根据年龄组,市场分为儿童和成人。根据分销渠道,MEA呼吸道感染治疗市场分为医院药房、网上药房和零售药房。

细分分析:

在药品方面,抗生素细分市场占据主导地位到 2023 年,MEA 呼吸道感染治疗市场份额最大。预计 2023 年至 2031 年复合年增长率最高。呼吸道感染包括一系列疾病,包括支气管炎、肺炎和鼻窦炎,通常由细菌病原体引起。抗生素针对并消除这些有害细菌,减少炎症并促进更快的康复。呼吸道感染常用抗生素包括青霉素类、头孢菌素类、大环内酯类、氟喹诺酮类、四环素类,每种药物都有独特的作用机制和细菌靶点。

根据疾病适应症,下呼吸道感染领域开展了到 2023 年,市场份额将更大。预计 2023 年至 2031 年复合年增长率将更高。下呼吸道感染 (LRTI) 是影响肺部和支气管的感染,通常由细菌、病毒或真菌病原体等引起。肺炎、支气管炎和细支气管炎等疾病属于 LRTI 范畴,通常表现出咳嗽、胸部不适、呼吸急促和发烧等症状。肺炎是一种严重的 LRTI,涉及肺组织的炎症和感染,导致肺实变(肺的某些区域或整个器官)和气体交换受损。

通过给药途径,口腔部分保持MEA呼吸道感染治疗市场的更大份额;预计同一细分市场在 2023 年至 2031 年期间将出现更高的复合年增长率。经常使用阿莫西林、阿奇霉素或多西环素等口服抗生素来对抗引起呼吸道感染的细菌病原体。除抗生素外,口服皮质类固醇还可减轻严重哮喘或慢性阻塞性肺疾病 (COPD) 恶化时的炎症。口服抗病毒药物(例如奥司他韦)用于治疗病毒性呼吸道感染(例如流感)。口服途径的共同优点包括给药方便、患者依从性和全身药物分布。

从年龄组来看,2023年成人细分市场在MEA呼吸道感染治疗市场中占有较大份额。预计儿科细分市场在 2023 年至 2031 年期间将实现更高的复合年增长率。儿童呼吸道感染的高患病率是推动有效治疗方案需求的一个关键因素。此外,人们对儿童呼吸道感染早期诊断和治疗重要性的认识不断提高,医疗技术的进步导致新的、更有效的治疗方案的开发,以及对预防性医疗措施的日益关注等因素也有助于儿科细分市场的增长。

就分销渠道而言,预计医院药房细分市场将在 2023 年至 2031 年期间占据重要的市场份额。医院药房是医疗保健系统的关键组成部分;它们在治疗需要静脉或肌肉注射药物的急性和严重呼吸道感染方面尤其发挥着至关重要的作用。这些药房负责采购;储存;分发抗生素、抗病毒药物、皮质类固醇和其他呼吸道感染治疗药物,同时确保将其安全及时地运送到医院的住院和门诊环境中。

区域分析:

因此,人们的认识不断增强人们对呼吸道感染早期诊断和治疗重要性的认识可能会促进 MEA 呼吸道感染治疗市场在未来几年的增长。市场分为南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区。 2023年,沙特阿拉伯拥有最大的MEA呼吸道感染治疗市场份额。由于该国呼吸道感染患病率上升,沙特阿拉伯的市场正在经历显着增长。空气污染、吸烟和拥挤的生活条件等因素导致该国呼吸道感染的高发。沙特王国慢性阻塞性肺病的患病率为 2.4%;此外,根据过去三十年进行的研究,儿童和成人中哮喘的患病率在 8% 至 25% 之间。沙特重症监护协会以极其协调和结构良好的方式向沙特阿拉伯医疗保健从业人员提供呼吸治疗方面的临床教育和培训。因此,呼吸道感染的患病率不断上升、人们对医疗保健的认识不断增强以及政府的有利举措正在推动沙特阿拉伯呼吸道感染治疗市场的增长。

竞争格局和主要公司:

MEA 呼吸道感染治疗市场预测可以帮助利益相关者规划其增长战略。雅培实验室、阿斯利康公司、Alembic Pharmaceuticals Ltd.、勃林格殷格翰国际有限公司、葛兰素史克公司、梯瓦制药工业有限公司、诺华公司、罗氏公司、赛诺菲公司、Orion Corporation 和 Julphar 都是该报告中介绍的知名参与者。 MEA 呼吸道感染治疗市场报告。这些公司专注于各种战略(包括有机和无机),以满足不断增长的消费者需求并扩大其专业产品组合的产品范围。 MEA呼吸道感染治疗公司采取的主要策略包括新技术推出、现有产品开发和地域扩张。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are the driving factors for the MEA Respiratory Tract Infection Treatment Market?

Key factors driving the market growth include the rising cases of respiratory infections in the Middle East, and increasing awareness related to respiratory tract infections. However, the lack of research focused on respiratory therapeutics hinders market growth. Further, the advent of antiviral treatment for MERS is expected to bring new MEA respiratory tract infection treatment market trends in the coming years.

Who are the major players in the MEA Respiratory Tract Infection Treatment Market worldwide?

The MEA Respiratory Tract Infection Treatment Market majorly consists of the players such Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Orion Corporation, and Julphar.

Which segment is dominating the India Respiratory Tract Infection Treatment Market?

In terms of drug, the antibiotics segment held the largest MEA respiratory tract infection treatment market share in 2023. The same is anticipated to register the highest CAGR during 2023–2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens.

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023. It is further anticipated to register a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others.

By route of administration, the oral segment held a larger share of the MEA respiratory tract infection treatment market; the same segment is anticipated to register a higher CAGR during 2023–2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections.

In terms of age group, the adult segment held a larger share of the MEA respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. The high prevalence of respiratory tract infections among children is a key factor driving the need for effective treatment options.

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications.

What are Respiratory Tract Infection Treatment?

Respiratory tract infections, or RTIs, are infections of the sinuses, throat, airways, or lungs. Though most RTIs resolve on their own, occasionally, a visit to your doctor may be necessary. The MEA respiratory tract infection treatment market report emphasizes the key factors driving the market and depicts the developments of prominent players.

The List of Companies - MEA Respiratory Tract Infection Treatment Market

  1. Abbott Laboratories
  2. AstraZeneca plc
  3. Alembic Pharmaceuticals Ltd.
  4. Boehringer Ingelheim International GmbH
  5. GlaxoSmithKline plc
  6. Teva Pharmaceutical Industries Ltd
  7. Novartis AG
  8. F. Hoffmann-La Roche AG
  9. Sanofi S.A.
  10. Orion Corporation
  11. Julphar

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports